of IIM and certain other autoimmune diseases 12 . Such aggregation of autoimmune diseases within families of patients with IIM suggests that shared genetic and/or environmental factors might contribute to disease risk. However, large, well-powered, epidemiological studies are needed to robustly evaluate these data. Notably, in 2015, a systematic review demonstrated that the reported incidence and prevalence rates for IIMs have increased over time 13 . Although this finding might reflect a true increase in disease burden, this increase could also be due to a wider recognition or more accurate recording of disease than in the past.
In contrast to the more common immune-mediated diseases, in which extensive meta-analyses have been conducted, a relatively small number of genetic risk variants has been identified for IIM. This small number likely reflects the sample sizes of patients with IIM, as well as the marked heterogeneity of these complex diseases, and highlights the importance of collaborative endeavours. Most large genetic studies of IIMs have focused on populations of European ancestry. Further large-scale studies are required to establish whether variants, pathways and gene-environment interactions are shared across different ethnic groups.
HLA loci associated with IIM
Genome-wide single-nucleotide polymorphism (SNP) association studies in adult and juvenile individuals of European ancestry who have dermatomyositis or polymyositis identified the strongest disease associations within the MHC region on chromosome 6 (REFS 14, 15) , one of the most complex regions of the genome, which has a high concentration of genes encoding proteins with immunological functions. The development of the Immunochip (Illumina, USA), a cost-effective genotyping array that includes ~200,000 genetic variants associated with autoimmune diseases, combined with accurate imputation of HLA alleles and amino acids from SNP data 16 , greatly improved our ability to dissect HLA associations. The Myositis Genetics Consortium conducted the largest genetic study in IIM to date, which included 2,566 patients with IIM from 14 countries. The study demonstrated the strongest disease association with alleles of the HLA 8.1 ancestral haplotype -HLA-DRB1*03:01 and HLA-B*08:01 in polymyositis and dermatomyositis, respectively -and conditional analysis revealed that multiple variants of this haplotype might contribute independently to disease risk 17 . In IBM, HLA-DRB1*03:01, HLA-DRB1*01:01 and HLA-DRB1*13:01 were independently associated with disease 18 ; the latter two alleles are uniquely associated with IBM. Different risk factors are seen in particular ethnic groups, including HLA-DRB1*08:03, which is associated with IIM in Japanese patients 19 and HLA-DQA1*01:04 and HLA-DRB1*07, which are associated with dermatomyositis in Chinese populations 20 . Specific amino acid associations in the HLA region, such as position 57 of HLA-DQB1, position 77 of HLA-DRB1*03:01, and positions 26 and 11 of HLA-DRB1*03:01, differentiate dermatomyositis, poly myositis and IBM, respectively 17, 18 , and suggest different predominating pathophysiologies in different clinical subgroups. Conversely, although HLA allele associations differ across various ethnic populations, the amino acid associations might be consistent. Amino acid sequence variations might alter the structure of the HLA molecule's peptide-binding groove and thereby increase disease susceptibility by influencing antigen repertoires and the affinity of peptides presented to the immune system. If so, computational modelling of predicted antigen-HLA binding to identify the immunogenic peptides could help to determine disease mechanisms.
The finding that different HLA alleles have been associated with various myositis-specific autoantibody (MSA)-defined subgroups 21 agrees with the finding that many MSAs are mutually exclusive. In general, HLA risk alleles are more strongly associated with MSA-defined subgroups than clinically defined subgroups (which are less homogeneous than the MSA-defined subgroups) despite smaller sample sizes in the MSA subgroups. For example, the presence of anti-histidyl-tRNA synthetase (anti-Jo1) autoantibodies in IIM is strongly associated with multiple alleles of the 8.1 ancestral haplotype, including HLA-B*08:01, DQB1*02:01 and DRB1*03:01, particularly when multiple alleles are considered together as a haplotype 15 . The presence of other autoantibodies, including autoantibodies to Mi2, small ubiquitin-like modifier activating enzyme (SAE), melanoma differentiation-associated protein 5 (MDA5), signal recognition particle (SRP), transcription intermediary factor 1 (TIF1) and PL7, have been associated with specific HLA alleles 21, 22 . Although most HLA associations are the same in adult and juvenile IIM phenotypes, HLA associations can occasionally differ between adult and juvenile patients, as is the case with anti-3-hydroxy-3-methylglutaryl-coA reductase (HMGCR) autoantibodies, which are associated with HLA-DRB1*11:01 and HLA-DRB1*07:01 in adult and juvenile patients with IIM, respectively 23, 24 .
Key points
• Multiple independent associations within the HLA 8.1 ancestral haplotype are the strongest genetic risk factors for idiopathic inflammatory myopathies (IIMs).
• Although some associations overlap with those for other autoimmune diseases, other genetic risk factors are unique to certain IIM phenotypes, suggesting that these phenotypes have different pathophysiologies.
• In addition to drug-induced myositis, epidemiological data support a role for infections, prior lung disease, physical exertion, collagen implants, ultraviolet radiation and smoking in the development of IIM phenotypes.
• Although the disease mechanisms for IIM are ill-defined, both the innate immune system (including cytokines and chemokines) and adaptive immune system (including autoantibodies and antigen-specific T cells) are probably involved.
• Several non-immune-mediated mechanisms contribute to IIM pathogenesis, including cell-stress pathways, free radicals, altered energy metabolism, protein homeostasis and mitochondrial damage.
• Multidisciplinary collaborative approaches, focused use of resources and better investigative tools are needed to define additional risk and protective factors and pathogenic mechanisms, to cure and prevent the development of IIM.
Rimmed vacuoles
Spaces within the cytoplasm of a muscle cell with a purplish staining rim on trichrome staining.
Functional annotation
Characterization of the function assigned to each gene product or genetic variant.
Expression quantitative trait loci
(eQTLs). Genomic loci that regulate gene expression.
Non-HLA loci associated with IIM
Several non-HLA loci have been associated with IIM (TABLE 1) , including PTPN22 (REF. 17, 25 ); this locus was associated with polymyositis (reaching genome-wide significance, defined as P < 5 × 10 −8 ), but not with adult or juvenile dermatomyositis 17 , again suggesting that different clinical subgroups have different pathophysiologies. Other genes, including STAT4, TRAF6 and UBE2L3 in various subtypes of IIM 17, 26 ; PLCL1 and BLK in dermatomyositis 14, 27 ; and CCR5 in IBM 18 , have been associated with disease, reaching a suggestive level of significance (defined as P < 2.25 × 10 −5 ). One study linked complement 4A (C4A) deficiency, owing to copy number variation, to an increased risk of developing juvenile dermatomyositis, although the strongest risk factor identified in the study was the presence of HLA-DRB1*03:01 along with C4A deficiency 28 . In IBM, sequencing of candidate genes involved in related neuromuscular or neurodegenerative diseases 29, 30 and whole-exome sequencing of genes encoding proteins overrepresented in the skeletal muscle rimmed vacuoles of patients with IBM 31 identified rare variants in VCP, SQSTM1 and FYCO1 associated with IBM, suggesting impaired autophagy as a mechanism of IBM pathogenesis.
Pathways implicated in IIM pathogenesis
By identifying the genes associated with IIM, studies can focus on the molecular pathways involved and thereby improve our understanding of IIM pathogenesis. The strong association between IIM subsets and HLA-DR and HLA-DQ genes supports a role for the adaptive immune system in the pathogenesis of IIM, as a key role of HLA class II molecules is to present antigens to T cells. The roles of other associated variants have been investigated by functional annotation -for example, by analysing the effects of coding variants on the translation of the encoded protein, and/or regulatory effects of non-coding variants on gene expression, through expression quantitative trait loci (eQTLs) analysis. Identification of eQTLs might also help to identify functionally relevant cell types through immune cell-specific eQTLs that affect spatial and temporal gene expression, the cellular response to stimulation and/or the magnitude of the response. Genes associated with IIM (TABLE 1) implicate both the innate and adaptive immune responses through, for example, the roles of PTPN22 and STAT4 in the T cell receptor pathway, or BLK, UBE2L3 and TRAF6 in B cells and the nuclear factor-κB (NF-κB) signalling pathway. In IBM, specific genes implicate both inflammatory and degenerative changes, including mitochondrial abnormalities, in disease pathogenesis.
Despite the small contribution of identified genetic variants to clinical phenotypes, drugs targeting the pathways affected by genetic variations might be disproportionately effective. In IIM, the application of drugs repurposed from other diseases will probably become more important as our understanding of disease mechanisms evolve. Refinements in defining the genetic factors that drive different phenotypes will be important in clinical decision-making for early and effective diagnosis, classification and therapeutic management, by targeting therapy to patients most likely to respond.
Missing heritability
The pathogenesis of IIM cannot be explained solely by genetic risk factors. Many of the variants identified have a relatively small effect on disease risk individually, and only 5.5%−16% of the phenotypic variance can be explained by genetic variants identified in Immunochip studies 32 . Following accepted models of genetic architecture, rare variants, including single nucleotide variants and copy number variants, are probably involved in rare diseases such as the IIMs but have not yet been extensively investigated. This postulate is illustrated by Mendelian forms of monogenic juvenile-onset disorders that share clinical and immunological features with juvenile dermatomyositis, such as chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) syndrome 33 .
Environmental risk factors
Although a number of genes have been associated with the IIMs, the physiological effect of these genes might depend on their activation or modification by environmental factors. Compared with genetic studies, however, fewer investigations have explored the role of environmental exposures in the development of IIM. Thus, the field is decades behind other areas, such as oncology, which has identified modifiable risk and protective factors for different cancers; by contrast, in many cases, only a single or small number of studies have identified specific environmental factors associated with particular IIM phenotypes.
Influences on autoimmunity
Multiple lines of evidence suggest that autoimmune diseases have an environmental component: the concordance rates for autoimmune diseases in mono zygotic twins is much less than 50% 34, 35 ; there are strong temporal associations between certain exposures (infectious agents and drugs in particular) and the subsequent development of some autoimmune diseases [36] [37] [38] ; in some individuals, disease improves after removing a suspected environmental agent (dechallenge) and/or worsens or
Box 1 | The idiopathic inflammatory myopathies
• The idiopathic inflammatory myopathies (IIMs), or myositis, are a heterogeneous group of rare systemic disorders that can involve multiple organ systems but are defined by chronic muscle inflammation • The major IIM phenotypes are dermatomyositis, polymyositis and necrotizing myopathy, which have a female predominance 84 and inclusion body myositis, which has a male predominance 192 • Childhood-onset and adult-onset forms of IIM share many clinical, pathological and genetic features but differ in the frequency of specific phenotypes, the response to therapies and prognosis • Certain autoantibodies directed against translational and transcriptional components are found only in the IIMs and define unique clinical, genetic and prognostic groups • Both immune and non-immune pathways contribute to muscle damage and weakness • Therapy in IIM includes immunosuppressive agents to decrease inflammation and rehabilitation with exercise to strengthen remaining muscle reoccurs after re-exposure to the suspected agent (rechallenge) [38] [39] [40] ; the incidence of many autoimmune diseases has increased over time 41, 42 ; there are seasonal and geographical variations in disease onset and in birth dates of individuals who have developed an autoimmune disease 38, [43] [44] [45] [46] ; data from relevant animal models have demonstrated the plausibility of multiple environmental agents potentially triggering autoimmune disease [47] [48] [49] ; the major genetic risk factors for autoimmunity are polymorphic genes that regulate responses to environmental agents 50, 51 ; variations in the human immune system are largely driven by nonheritable influences 52 ; and associations between specific exposures and autoimmune diseases have been documented in large epidemiological studies 53, 54 . In addition to their role as possible initiators of autoimmunity, environmental factors might alter the rate of progression to clinical disease, the specific manifestations of disease expression and/or the course of illness 38, 55 . After certain disease-initiating exposures, decades can pass before autoimmune disease manifests, and, as with many cancers, there can be a progression through stages from autoimmunity to preclinical disease with immune alterations to classifiable autoimmune disease 56 . A panel of international investigators convened by the US National Institute of Environmental Health Sciences in 2012 defined a number of well-supported associations between environmental exposures and autoimmune diseases 54 and proposed criteria to define environmentally associated autoimmune diseases in clinical care and epidemiological settings 40 . Thus, there are many possible ways in which environmental agents might influence individuals over the lifetime to result in perturbations that could eventually result in the autoimmune phenotypes we recognize today. However, it is critical to develop consensus on how to best recognize and diagnose environmentally associated autoimmunity.
Specific environmental agents in IIM
As with other autoimmune diseases, many studies of environmental factors in IIM have been based on animal models, case reports and/or case series, and have suggested environmental risk factors that might vary in IIM phenotypes 37, 57 . Such studies have investigated possible disease associations of selected IIM phenotypes with many viral, bacterial and parasitic infections 58 ; foods and dietary supplements 59 ; collagen and silicone implants 60, 61 ; dozens of biologic agents and chemicals prescribed as drugs 50 ; seasonal variations 14 ; birth date assocations 46 ; exposure to ultraviolet light 45, 62, 63 ; and occupational exposures to dust, gases or fumes 64, 65 . A number of specific infectious agents are implicated in IIM pathogenesis on the basis of reported occurrences of suspected infection-induced disease or biological plausibility from animal models 56 . Examples include hepatitis B virus in polymyositis 66 and dermatomyositis 67 ; hepatitis C virus in IBM 68 ; retroviruses, particularly HIV and human T-lymphotropic virus-1, in poly myositis 69 , dermatomyositis 70 and IBM 71, 72 ; Toxoplasma spp. and Borrelia spp. in polymyositis and dermatomyositis 73 ; and influenza, picornavirus and echovirus in poly myositis, dermatomyositis and juvenile dermatomyositis 58 . Case reports have documented associations between IIM development and medications, including d-penicillamine in polymyositis and dermatomyositis 74 ; therapeutic cytokines, especially interferons 75 and anti-TNF agents, in dermatomyositis 76 ; and statins in polymyositis, dermatomyositis, necrotizing myopathy and IIM with anti-HMGCR autoantibodies [77] [78] [79] . On the basis of case series and animal models, vaccines (especially those containing aluminum hydroxide) have been Nature Reviews | Rheumatology Fig. 1 | Possible pathways to idiopathic inflammatory myopathy phenotypes. The idiopathic inflammatory myopathies (IIMs) consist of multiple phenotypes, each of which might be defined by unique combinations of symptoms, signs and laboratory abnormalities. The major IIM phenotypes -polymyositis (PM), dermatomyositis (DM), necrotizing myopathy (NM) and inclusion body myositis (IBM) -are shown in the circle at the bottom. Each phenotype could result from different pathogenic mechanisms, including immunological and non-immunological processes, because of the interactions between genetic and environmental risk factors. Some combinations of genotypes and environmental exposures induce certain mechanisms and disease phenotypes, whereas other combinations might have no effect or could be protective. C4A, complement 4A; ER, endoplasmic reticulum; ROS, reactive oxygen species. hypothesized to be triggers of polymyositis, dermatomyositis and focal forms of myositis that affect only a selected extremity or part of the body 80 . Because of the limitations of animal models and case reports, and despite the rarity and heterogeneity of the IIMs, investigators have also assessed environmental risk factors by using epidemiological approaches. The environmental associations already discussed have in some cases, but not in others, been supported by the few epidemiological studies reported to date, which often addressed only a single exposure and have in many cases not been replicated. Those studies have sometimes had conflicting results, probably owing to differing approaches and study populations. The epidemio logical studies to date reveal a number of preliminary environmental associations (FIG. 2) : the risk of IIM seems to be increased after any infection and after gastrointestinal or respiratory tract infections or lung inflammation 81 ; the risk of polymyositis and dermatomyositis is decreased after upper respiratory tract infections 82 ; the risk of poly myositis or dermatomyositis is increased after excessive physical exertion 82 ; there is no association of vaccines with poly myositis or dermatomyositis 82 ; smoking is a risk factor for anti-Jo1 autoantibody-positive IIM (potentially interacting with HLA-DRB1*03 to increase this risk 83 , an effect similar to the HLA-smoking interaction seen in rheumatoid arthritis) and for myositis overlap syndromes 84 ; bovine collagen implants are associated with dermato myositis 60 ; and group A Streptococcus infections are associated with juvenile dermatomyositis 85 . Perinatal factors affecting mothers, including air pollution, smoking, and occupational exposure to dust and/or solvents, have also been proposed as important risk factors for juvenile dermatomyositis in a small study 86 . The compelling data that reveal a link between the environment and autoimmunity, as well as the remarkable increases in the incidence and prevalence of many autoimmune diseases for unknown reasons 41, 42, 87, 88 , underscore a critical need for both exploratory and confirmatory environmental investigations in this understudied field. Identifying factors that protect against disease is also important to decrease the prevalence of autoimmune disease. Much more work is needed in these areas. Enumerating genetic and environmental risk and protective factors in carefully defined disease phenotypes is an important first step for discovering geneenvironment interactions that could lead to preventive strategies 38, 50 .
Genetic risk factors
Immune-mediated disease mechanisms Preliminary data suggest that many adaptive and innate immune mechanisms, as well as non-immune mechanisms, are involved in the development of IIM (FIG. 3) .
T cells in IIM
Several studies have demonstrated the presence of T cells and B cells, especially invasive, granzyme B and perforinexpressing cytotoxic CD8 + effector T cells, in the muscles of patients with polymyositis or IBM 89, 90 . The invasion of CD8 + effector T cells into non-necrotic muscle fibres is considered a characteristic histo logical feature of polymyositis and IBM. The number of invading CD8 + and CD57 + T cells in the muscle correlates with the size of large granular lymphocyte populations in the blood of patients with IBM, and the auto immune T cell expansion is proposed to evolve into a neoplastic-like or overtly neoplastic disorder of T cell aggressiveness 91 . In the 1990s, investigations demonstrated the presence of clonal γδ T cells in the muscle of patients with polymyositis and, in 2012, investigators showed that these γδ T cells recognize aminoacyl-tRNA synthetases (which are involved in protein synthesis and are targets of MSAs), suggesting a potential link between γδ T cells and autoantibody responses in IIM [92] [93] [94] . In some patients with IIM, the presence of γδ T cells in their muscle tissue seems to be associated with increased responsiveness to ciclosporin A and/or corticosteroid therapy 92, 95 . Muscles affected by IIM also contain some unique subsets of highly cytotoxic, apoptosis-resistant, pro-inflammatory T cells, such as CD28 null T cells (both CD4 + CD28 null and CD8 + CD28 null T cells) [96] [97] [98] . A persistence of CD244 + [102] [103] [104] . Autoantibodies are present in more than half of all patients with IIM. The presence of MSAs, such as anti-Jo1, anti-Mi2, anticytosolic 5ʹ-nucleotidase 1A (cN1A) and anti-HMGCR autoantibodies, are well described in patients with polymyositis, dermatomyositis, IBM, and necrotizing myopathy, respectively 105 . In addition to this work, which confirmed many genetic and clinical associations with the classic MSAs, studies have highlighted unique associations of newly identified autoantibodies with additional clinical phenotypes. For example, autoantibodies targeting MDA5 are associated with muco cutaneous lesions and severe lung disease in patients with dermatomyositis; autoantibodies that bind to nuclear matrix protein 2 (NXP2) are associated with joint contractures and calcinosis in juvenile dermatomyositis; and autoantibodies to SAE, TIF1γ and TIF1α are associated with malignancy in dermatomyositis 106 . Although the pathological roles of autoantibodies in IIM are unclear, their associations with distinct genotypes, clinical phenotypes and interferon expression patterns are strong. For example, the spectrum of clinical phenotypes in antisynthetase syndrome, a subtype of IIM defined by the presence of autoantibodies to aminoacyltRNA synthetases, includes interstitial lung disease, arthritis, Raynaud phenomenon and mechanic's hands. Levels of anti-Jo1 autoantibodies are also strongly associated with clinical outcomes, suggesting that anti-Jo1 autoantibody levels might be a useful biomarker of disease activity 107 . Furthermore, animal and in vitro studies demonstrate that the Jo1 autoantigen, histidyl-tRNA synthetase, might also play a role in inducing myositis 108 or function as a chemokine 109 . The role of autoantibodies in causing muscle damage and dysfunction is controversial because most of the autoantigens are intracellular and thus not easily accessible to circulating autoantibodies; however, additional work focusing on their role is warranted given their importance as biomarkers of unique genetic, clinical, therapeutic, and outcome phenotypes. Although causeand-effect relationships between autoantibodies and disease phenotype and activity currently are not clear, the strong associations of autoantibodies with clinical phenotypes and disease severity are immensely useful for the diagnosis and prognosis of IIM.
Innate immune cells
Antigen processing and presentation by professional antigen-presenting cells, such as dendritic cells (DCs), are critical to initiating the adaptive immune response, and the muscle microenvironment of IIM is enriched with both myeloid and plasmacytoid DCs [110] [111] [112] [113] [114] . The relative proportion of lymphocytes and macrophages in skeletal muscle seems to vary in different clinical entities; for example, in anti-HMGCR myopathy, M2 (alternatively activated) macrophages predominate over CD4 + and CD8 + T cells and CD123 + plasma cytoid DCs 115 . A predominance of M2 macrophages in skeletal muscle is also seen in forms of inflammatory myopathy with abundant macrophages 116 . The presence of M2 macrophages is consistent with the known role of macrophages in skeletal muscle injury and repair 117 : M1 (classically activated) macrophages infiltrate the muscle in the early stages to help clear necrotic debris, whereas M2 macrophages arrive later to sustain tissue healing 118 .
Inflammatory mediators
The high serum levels of creatine kinase and other molecules that are released from skeletal muscle cells in patients with IIM could represent danger-associated molecular patterns, which sometimes serve as endogeneous Toll-like receptor (TLR) ligands. Skeletal muscle, as well as muscle-infiltrating cells, express abundant innate immune receptors, including TLRs [119] [120] [121] . Activation of innate immune receptors can lead to activation of NF-κB signalling and pro-inflammatory cytokine and chemokine secretion, which, in turn, further recruit immune cells into a milieu that is already ripe for antigen processing and presentation by dendritic cells. These immune cells and cytokines can then further activate T helper 1 (T H 1), T H 17 and T H 2 cells, as well as CD8
+ cytotoxic T cells and CD28 null T cells, which potentially damage muscle cells. Cytokines produced by these T helper cell subsets induce macrophages to polarize into pro-inflammatory M1 or pro-resolution M2 phenotypes.
Both pro-inflammatory and anti-inflammatory cytokines, as well as CXC-chemokines and CCchemokines, are expressed in IIM muscle; such mediators include T H 1 cytokines (TNF, IFNγ, IL-12 and IL-2), T H 2 cytokines (IL-4 and IL-13), T H 17 cytokines (IL-17, IL-22, IL-23, TNF-related weak inducer of apoptosis (TWEAK) and IL-6), T reg cytokines (IL-10 and transforming growth factor-β (TGFβ)) and innate immune cytokines (IL-1α, IL-1β and type I interferons (IFNα and IFNβ)). These cytokines coordinate various innate and adaptive immune response pathways, and some of them have the potential to cause muscle damage and weakness, depending on the stage of the disease 122, 123 . Similarly, both CXC-chemokines (CXC-chemokine ligand 9 (CXCL9) and CXCL10) and CC-chemokines (CC-chemokine ligand 2 (CCL2), CCL3, CCL4, CCL19 and CCL21) have a role in sustaining inflammatory responses in IIM muscle 124 . In dermatomyositis, evidence from the past decade has demonstrated high levels of type I interferon in the muscles of patients, which is associated with perifascicular atrophy [125] [126] [127] [128] . Genes induced by type I interferons (either IFNα or IFNβ) were overexpressed in the muscle, skin and blood, of patients with dermatomyositis, and in some [129] [130] [131] , but not all 132 , of those studies, the levels of these genes correlated with disease activity. Evidence suggests that myeloid DCs are a major source of type I interferons in the muscle of patients with dermatomyositis 111 . Type I interferons affect immune cells either directly, through type I interferon receptor signalling, or indirectly, by inducing the production of chemokines, by inducing the secretion of cytokines such as IL-15 (which regulate natural killer cell and memory CD8 + T cell proliferation), by stimulating DCs (which, in turn, activate naive T cells) or by inducing the differentiation of monocyte-macrophage lineage cells 133 . IFNβ can induce reactive oxygen species and mitochondrial damage in dermatomyositis 134 , which provides an important link to the cause of the functional impairment in this disorder. Induction of tissue inflammation and autoimmunity by IFNα involves direct , and danger-associated molecular patterns (DAMPs) to receptors on skeletal muscle cells. Binding of these receptors and/or aberrant overexpression of MHC class I molecules can induce various signalling events including activation of the nuclear factor-κB (NF-κB) pathway and/or the endoplasmic reticulum (ER) stress response. These events can lead to proteasome activation and autophagy, which can result in dysregulated protein homeostasis, inflammasome activation, pro-inflammatory cytokine and chemokine production, and activation of cell death mechanisms (for example, pyroptosis or pyronecrosis) in skeletal muscle. Signalling through cytokine receptors (for example, the type I interferon receptor (IFNAR) and/or IL-1 receptor (IL-1R)) can cause dysfunction in mitochondrial metabolism and/or production of reactive oxygen species (ROS) and/or nitric oxide (NO), potentially leading to deficits in energy-generating metabolic pathways in skeletal muscle. These non-immune mechanisms (alone or in combination) contribute to muscle weakness and fatigue, common features of IIMs. TCR, T cell receptor; TLR, Toll-like receptor.
◀ toxic effects on tissue as well as provocation of destructive bystander immune responses 135 . IFNα mediates a long-lasting and preferential overexpression of MHC class I in non-immune cells, such as human pancreatic beta cells and thyroid follicular cells, which usually lack MHC class I expression. This finding suggests that IFNα might amplify antigen presentation in T1DM and Hashimoto thyroiditis 136, 137 . The increased expression of MHC class I molecules on skeletal muscle cells of patients with IIM probably leads to increased susceptibility of these cells to cytotoxic T cell attack and endoplasmic reticulum (ER) stress-mediated cell death 138, 139 . On the basis on these findings, neutralization of type 1 interferon has been explored as a treatment option in dermatomyositis and polymyositis 140 .
Non-immune-mediated disease mechanisms
Apart from the inflammatory pathomechanisms discussed in the previous section, mounting evidence suggests that several non-immune-mediated mechanisms also operate in IIM (an overview of the topic has been provided elsewhere 141, 142 ). In general, these mechanisms fuel inflammation via a positive feedback loop, affect muscle contraction and cause muscle weakness, imbalance muscular protein homeostasis and lead to atrophy and mostly irreversible structural damage of muscle fibres. The suggestion that non-immune-mediated mechanisms are clinically relevant in IIM derives from a number of key findings: the muscular inflammation identified by muscle biopsy and MRI does not always correlate with the clinical severity; the effects of immuno suppressive treatments can be limited; and several non-inflammatory mechanisms, including cell stress and degenerative mechanisms, are obvious in many muscle biopsies 141, 142 . The most relevant non-immune mechanisms are discussed in this section.
ER stress
ER stress is one of the best-studied elements of nonimmune-mediated damage to skeletal muscle in all forms of IIM (overview in REF. 143 ). ER stress mechanisms include the unfolded protein response and the ER overload response. The unfolded protein response is characterized by upregulation of cAMP-dependent transcription factor 6α (ATF6α), eukaryotic translation initiation factor 2α-kinase 3 (EIF2α kinase, also known as PERK), serine/threonine-protein kinase/ endoribonuclease IRE1 (IRE1α) and the ER chaperones endoplasmin (also known as GRP94) and 78-kDa glucose-regulated protein (GRP78, also known as BiP). The collective function of these molecules is to reduce the protein overload and subsequent accumulation of unfolded proteins in the ER. The second ER stress pathway, the ER overload response, modulates inflammation by upregulating NF-κB signalling. Both ER stress pathways are activated in the muscle in all forms of IIM, including IBM 138, 144, 145 . Data from the past several years suggest that ER stress might even contribute directly to muscular weakness in IIM (reviewed elsewhere 146 ). The NF-κB pathway has been shown to be activated in IIM 147, 148 . At the same time, relevant molecules of the immunoproteasome, such as proteasome subunit-β type 5 (PSMB5, also known as β1i) and PSMB8 (also known as β5i), are present in the muscles of patients with IIM 149 . The NOD-, LRR-and pyrin domain containing protein 3 (NLRP3) inflammasome has also been shown to be upregulated in dermatomyositis and polymyositis, in association with elevated levels of IL-1β and IL-18 (REF. 150 ). Since ER stress is known to induce the NLRP3 inflammasome in other cell systems 151 , ER stress is possibly a crucial factor in the muscle pathology of IIM by inducing molecules of the inflammasome and immunoproteasome pathways.
Other key factors
Free radicals are key factors in muscle fibre damage in all forms of IIM 152, 153 , and these molecules are speculated to contribute directly to muscle weakness 146 . In a mouse model of chronic inflammation (mice overexpressing TGFβ), muscular atrophy was mediated by inflammation, production of reactive oxygen species, mitochondrial damage and caspase activation. The mitochondrial damage and muscle atrophy were efficiently downmodulated following supplementation with red grape polyphenols, a potential dietary antioxidant, despite the mice showing continued muscle inflammation 154 . TNF-related apoptosis-inducing ligand (TRAIL) expression is upregulated and associated with autophagy and cell death in the skeletal muscle of patients with IIM 155 . In IIM muscle fibres, the expression of heat-shock proteins HSP70 and HSP90 (REF.
156
) and the alarmin high mobility group box protein 1 (HMGB1) 157 is increased compared with healthy controls; HMGB1 functions via TLR4 and is thought to mediate muscular inflammation and weakness [158] [159] [160] . Consistent findings relating to increased HMGB1 expression have been reported in experimental models of autoimmune myositis in rodents 161 . Dysregulation of HMGB1 might also be relevant for the regenerative potential of skeletal muscle in IIM, because HMGB1 is an important factor during recovery and is required for the patient to regain muscle function after severe damage 162 ; thus, HMGB1 could serve as a prognostic marker in severe IIM 163 .
Inclusion body myositis
The largest body of evidence for non-immune-mediated mechanisms in IIM is available for IBM 164 . The pathogenesis of IBM includes many pathways involved in protein homeostasis and cell stress mechanisms, and several of these pathways seem to be linked directly to inflammation.
Protein homeostasis and the heat shock response. A variety of unwanted and defective proteins that should be removed from the cell, including β-amyloid and its associated proteins, can accumulate in the muscle of patients with IBM [165] [166] [167] . In IBM, intracellular accumulation of abnormal or no-longer-needed proteins in muscle fibres is hypothesized to cause or aggravate cell stress pathways, thus leading to structural damage and weakness of the fibres. In patients with IBM, proteomic analysis of vacuolated fibres identified the autophagic adaptor protein FYVE domains and coiledcoil domain-containing protein 1 (FYCO1) as a novel component in the rimmed vacuoles 31 . The accumulation of FYCO1 was associated with a missense variant of FYCO1 in 11% of patients with IBM, which supports the hypothesis of impaired autophagic activity in IBM.
Heat shock protein expression has been demonstrated in the muscles of patients with IBM and in human muscle fibres cultured in experimental conditions that mimic either inflammatory or degenerative aspects of IBM pathology 168, 169 . One of the most commonly expressed heat shock proteins in IBM, α-crystallin B chain (also known as αB-crystallin or CRYAB or HSPB5), seems to be an early element in the pathological cascade, as this protein is upregulated in healthy muscle fibres 168, 170 . Heat-shock factor protein 1 (HSF1) can ameliorate cell stress caused by aggregation of TAR DNA binding protein 43 (TDP43) in muscle cells 171 . In cell culture and animal models with pathological features of IBM, treatment with arimoclomol, a modulator of the heat-shock response, protected skeletal muscle cells against protein accumulation and cell stress 172 . The same study showed that arimoclomol was safe and well-tolerated in patients with IBM 172 . Collectively, these data suggest that protein dyshomeostasis is an important non-immune element in the pathology of IBM and that this process is associated with a heat-shock response that could be a suitable target for therapy in future clinical trials.
Dysregulation of autophagy.
Several lines of evidence have demonstrated malfunction of the autophagic machinery in IBM 173, 174 . Macroautophagy is active during the accumulation of β-amyloid in vacuoles (although whether macroautophagy causes β-amyloid to accumulate is not yet known) 175 , and this process depends on extracellular signal-regulated kinase (ERK) signalling 176 . Other autophagy adaptor molecules have been implicated in IBM, including sequestosome 1 (SQSTM1; also known as p62) 177 , next to BRCA1 gene 1 protein (NBR1) 178, 179 and nuclear factor erythroid 2-related factor 2 (NRF2; also known as NFE2L2) 180 . Collectively, these data indicate that autophagy is a relevant mechanism in IBM pathology and provide the rationale for a newly completed, placebo-controlled clinical trial of rapamycin, an immunosuppressant that activates macroautophagic activity, in patients with IBM (the results of which are not yet published) 181 .
Mitochondrial abnormalities and free radicals. Apart from inflammation and protein accumulation, mitochondrial abnormalities, such as cytochrome c oxidase deficiency in muscle fibres, are hallmarks of IBM. Several mitochondrial defects have been demonstrated in the muscle tissue of patients with IBM 182 . Such mitochondrial changes are associated with oxidative damage 183 , inflammatory mediators 184 and functional impairment of muscle strength 185 . Signs of mitochondrial dysfunction have also been shown in a mouse model of IBM, in which mice overexpressing human amyloid precursor protein develop IBM-like pathological features owing to the accumulation of amyloid precursor protein in the skeletal muscle 186 and in human muscle cells following adenovirus-mediated upregulation of amyloid precursor protein in vitro 187 . In addition to the reports of free radical generation in IIM, production of nitric oxide has been demonstrated in IBM in association with accumulation of β-amyloid and inflammation in skeletal muscle as well as in different cell culture systems that mimic relevant aspects of IBM 188, 189 .
Targeting non-immune-mediated pathways
Non-immune-mediated mechanisms are relevant in all forms of IIM and can result in structural damage to muscle fibres, cause direct weakness of the muscle, or reciprocally fuel inflammatory cell stress pathways. Many of these pathways are far from being understood and present possibly novel areas of mechanistic studies and therapeutic approaches. Novel treatment strategies for IIMs include inhibition of the ubiquitin proteasome pathway in skeletal muscle using bortezomib 190 . Future treatments should include therapies that scavenge free radicals and/or target other damage signals, such as alarmins and non-inflammatory mediators. Such therapies could reduce structural damage to muscle fibres and ameliorate weakness, particularly when these features are mediated by a functional impairment of muscle homeostasis and energy metabolism, such as mitochondrial dysfunction.
Conclusions
Studies in the past decade have elucidated possible genetic and environmental risk factors, as well as possible immune and non-immune mechanisms, that result in the development of the various IIM phenotypes. However, current paradigms are often biased by certain assumptions and use nonstandardized disease or phenotype definitions that can limit our understanding and result in the assessment of different entities by different investigators. Current studies emphasize the importance of using mutually exclusive and stable pheno types to minimize confounding factors and to allow for greater statistical power by using more homogeneous groups and smaller sample sizes, as is necessary for rare diseases such as the IIMs. Multidisciplinary IIM collaborative study groups have had a key role in developing consensus on how to define and study IIM phenotypes (see the Reviews by Lundberg et al. 1 and Rider et al. 2 on classification and outcome assessment, respectively, in this journal).
In the future, emphasis needs to be placed on multidisciplinary, collaborative investigations of genetic and environmental risk factors and their interactions, as well as pathogenic mechanisms, in homogeneous, welldefined phenotypes, utilizing the many IIM registries and repositories that have been developed to maximize cost-effectiveness 191, 84 . More investment in these areas seems appropriate to develop preventive strategies and to allow for innovative approaches to treatment as new pathways of disease are discovered.
